Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2261 to 2270 of 2733 total matches.
Herpes Zoster Vaccine (Zostavax)
The Medical Letter on Drugs and Therapeutics • Sep 11, 2006 (Issue 1243)
% of adults in the US have
had varicella and are at risk for HZ.
1
More than one
million new cases of HZ ...
A live attenuated varicella-zoster vaccine (Zostavax - Merck) has been approved by the FDA for prevention of herpes zoster (HZ; zoster; shingles) in persons ≥60 years old. Each dose of Zostavax contains about 14 times as much varicella-zoster virus (VZV) as Varivax, which has been used in the US since 1995 to vaccinate against varicella (chicken pox).
Lubiprostone (Amitiza) for Irritable Bowel Syndrome with Constipation
The Medical Letter on Drugs and Therapeutics • Jul 14, 2008 (Issue 1290)
), which was previously
approved for treatment of chronic idiopathic constipation in adults,
1
has now ...
Lubiprostone (Amitiza), which was previously approved for treatment of chronic idiopathic constipation in adults, has now also been approved in a lower dose for use in women with irritable bowel syndrome with constipation (IBS-C). Since tegaserod (Zelnorm) has been withdrawn from the market,2 lubiprostone is the only drug approved by the FDA for treatment of this common condition.
Methylnaltrexone (Relistor) for Opioid-Induced Constipation
The Medical Letter on Drugs and Therapeutics • Aug 11, 2008 (Issue 1292)
(~50% in urine)
Table 1. Pharmacology
OPIOID-INDUCED CONSTIPATION — Although
patients develop ...
The FDA has approved subcutaneous injection of methylnaltrexone (Relistor - Wyeth/Progenics), a selective mu-opioid receptor antagonist, for treatment of opioid-induced constipation in patients with advanced illness (such as incurable cancer or end-stage chronic obstructive pulmonary disease) who are receiving palliative care.
Edluar - A New Sublingual Formulation of Zolpidem
The Medical Letter on Drugs and Therapeutics • Apr 19, 2010 (Issue 1336)
Table 1. Pharmacology
*10 mg dose
Edluar (Meda), a new sublingual tablet formulation ...
Edluar (Meda), a new sublingual tablet formulation of the benzodiazepine receptor agonist zolpidem
(Ambien, and others), has been approved by the FDA for treatment of insomnia.
Ofatumumab (Arzerra) for CLL
The Medical Letter on Drugs and Therapeutics • Jun 28, 2010 (Issue 1341)
(Cytoxan, and others) and rituximab (Rituxan).
1
Options for patients who are refractory to initial ...
The FDA has approved ofatumumab (Arzerra – GlaxoSmithKline), a human anti-CD20 monoclonal
antibody, for treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine (Fludara, and others) and alemtuzumab (Campath). It is the second anti-CD20 antibody approved for treatment of CLL; rituximab (Rituxan), a chimeric murine/human antibody, was the first.
Extended-Release Hydrocodone (Zohydro ER) for Pain
The Medical Letter on Drugs and Therapeutics • Jun 09, 2014 (Issue 1444)
, and others).1
PHARMACOLOGY — Hydrocodone is a semisynthetic
opioid. It is metabolized primarily by CYP3A4 ...
The FDA has approved an extended-release oral formulation
of the opioid agonist hydrocodone (Zohydro ER –
Zogenix) for management of pain severe enough to
require continuous, long-term therapy and for which
alternative treatment options are inadequate. Zohydro ER
is the first single-ingredient hydrocodone product to be
marketed in the US. Hydrocodone has been available for
years in combination with acetaminophen (Vicodin, and
others) or ibuprofen (Vicoprofen, and others).
Calcipotriene/Betamethasone Foam (Enstilar) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Apr 11, 2016 (Issue 1492)
tolerated
than either component alone.1,2 Phototherapy and
systemic therapy, including biologic agents ...
The FDA has approved Enstilar (Leo), an aerosol
foam formulation of the synthetic vitamin D3 analog
calcipotriene and the high-potency corticosteroid
betamethasone dipropionate, for topical treatment
of plaque psoriasis in adults. Topical ointment and
suspension formulations of the same combination
have been available for many years.
BioThrax and Anthrasil for Anthrax
The Medical Letter on Drugs and Therapeutics • May 09, 2016 (Issue 1494)
such
as ciprofloxacin or doxycycline.1,2 Raxibacumab, an
intravenous human monoclonal antibody available
only ...
The FDA has approved anthrax vaccine adsorbed (AVA;
BioThrax – Emergent BioSolutions) for prevention of
anthrax disease in adults following exposure to Bacillus
anthracis and intravenous anthrax immune globulin
(Anthrasil – Emergent BioSolutions) for treatment of
inhalation anthrax in adults and children. AVA has been
available since 1970 for prevention of anthrax disease
in persons at high risk of exposure.
Etripamil Nasal Spray (Cardamyst) for Paroxysmal Supraventricular Tachycardia
The Medical Letter on Drugs and Therapeutics • Apr 13, 2026 (Issue 1752)
palpitations, dyspnea, chest discomfort, and,
rarely, syncope. About 1 in 300 persons in the US are
thought ...
The FDA has approved Cardamyst (Milestone), a
nasal spray formulation of the nondihydropyridine
calcium channel blocker etripamil, for conversion
of acute symptomatic episodes of paroxysmal
supraventricular tachycardia (PSVT) to sinus rhythm
in adults. Cardamyst is the first product containing
etripamil to be approved in the US. It is being marketed
as the only FDA-approved, self-administered, rapid-acting
treatment option for acute episodes of PSVT.
Med Lett Drugs Ther. 2026 Apr 13;68(1752):59-61 doi:10.58347/tml.2026.1752b | Show Introduction Hide Introduction
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
Opioids for Pain
A new CDC guideline for prescribing opioids for pain
recently became available.1 ...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.
